STOCK TITAN

Scilex Holding (SCLX) Stock News

SCLX Nasdaq

Welcome to our dedicated page for Scilex Holding news (Ticker: SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding stock.

Scilex Holding Company reports developments tied to its non-opioid pain management business, pharmaceutical assets and related healthcare investments. The company acquires, develops and commercializes products for acute and chronic pain, including ZTlido for postherpetic neuralgia, ELYXYB for acute migraine treatment in adults and Gloperba for prophylaxis of gout flares in adults.

Recurring Scilex news also includes material agreements, capital-structure actions, shareholder distributions involving Dream Bowl tokens, intellectual property and litigation counsel matters, strategic investments, clinical or regulatory disclosures, governance updates and operating and financial results.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.59%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none

FAQ

What is the current stock price of Scilex Holding (SCLX)?

The current stock price of Scilex Holding (SCLX) is $8.7 as of June 11, 2026.

What is the market cap of Scilex Holding (SCLX)?

The market cap of Scilex Holding (SCLX) is approximately 61.9M.